Verrica Pharmaceuticals Inc. has announced an amendment to its Collaboration and Licensing Agreement with Torii Pharmaceutical Co. Ltd. to initiate a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts. This trial is set to begin dosing the first patient in the United States in the fourth quarter of 2025. Verrica will receive a milestone payment of $8 million for the initiation of this study, which has commenced ahead of schedule. Additionally, Verrica is expected to receive a $10 million milestone payment upon the approval of YCANTH® for molluscum contagiosum in Japan, with a decision anticipated by the end of 2025. Torii will fund the first $40 million of the trial costs, covering approximately 90% of the current clinical budget. There are currently no FDA-approved prescription therapies for common warts, which affects an estimated 22 million patients in the United States. Trial results have not yet been presented, as the trial is in its initial stages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.